A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia
Latest Information Update: 22 Dec 2023
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Fibromyalgia; Pain
- Focus Registrational; Therapeutic Use
- Acronyms RALLY
- Sponsors Tonix Pharmaceuticals Inc
- 21 Mar 2022 Results presented in the Tonix Pharmaceuticals Holding Corp Media Release.
- 14 Mar 2022 According to a Tonix Pharmaceuticals Holding Corp media release, company plans to employ pharmacogenomic (PGx) techniques to compare the RALLY and RELIEF study populations, which may provide a path to precision medicine-based companion diagnostics for TNX-102 SL in FM.
- 14 Mar 2022 According to a Tonix Pharmaceuticals Holding Corp media release, topline results are expected in the first quarter of 2022.